Atrial Fibrillation: How Much Time Rhythm Control Actually Has
Two patients, both newly identified as candidates for a rhythm-control conversation, sit at opposite points in how far atrial structural remodeling has progressed. One is six weeks into her diagnosis; her atrium hasn't yet reorganized around the arrhythmia. The other has carried his for two years, and the reorganization is already complete. The pharmacology doesn't change — the question of whether it can still work does.
L.N., a 58-year-old woman who teaches middle-school science and coaches the after-school track team, first noticed her heart "skipping and racing" while grading lab reports six weeks ago — a sensation she initially dismissed as stress before it recurred twice more, each episode lasting under a day and resolving on its own. Her only known cardiovascular history is hypertension, diagnosed four years ago and well controlled on lisinopril; she has never had a prior arrhythmia, and nothing about her history suggested she was heading toward this consultation until an urgent-care ECG during her second episode confirmed atrial fibrillation.
Her transthoracic echocardiogram, obtained the following week, showed a left atrium of normal size and preserved ventricular function — unremarkable findings that matter here precisely because of what they rule out. Six weeks is a narrow window in atrial fibrillation's natural history: the arrhythmia is known to reinforce its own electrical and structural substrate the longer it persists, so a left atrium that hasn't yet dilated is not just a reassuring number but a marker that the remodeling process driving long-term treatment failure has barely begun. That timing is what turns this from a routine new diagnosis into a genuine strategic choice — whether to treat the rhythm now, while there is still a rhythm worth protecting, or manage the rate and wait.
Start rhythm control now, while there's still a rhythm worth protecting. Her atrium hasn't dilated, her ejection fraction is normal, and six weeks out from first detection is close to the window EAST-AFNET4 actually tested — recently diagnosed AF with a cardiovascular risk factor, in her case hypertension. That trial found early rhythm control reduced cardiovascular death, stroke, and hospitalization for heart failure or acute coronary syndrome compared with the usual rate-control- first approach — and it enrolled only patients diagnosed within the previous twelve months, at a median of about five weeks out, which is the population she is currently sitting in. Waiting doesn't preserve her options; every additional month in fibrillation is a month the atrium spends reinforcing the substrate we're trying to avoid.
I'd slow down before committing her to a daily antiarrhythmic. Three episodes in six weeks, each self-terminating, is not the same clinical picture as sustained AF — a meaningful fraction of first-detected atrial fibrillation doesn't recur at all once whatever precipitated it, if anything did, has settled. She's not in the emergency department in rapid AF; she's in my office with a normal echo and a diagnosis three episodes old. I'd rather rate-control her if she becomes symptomatic again, keep her anticoagulated, and reassess in a few months than start her on a drug she may not need.
The trial data support early rhythm control as a strategy across a population with recently diagnosed AF — they don't tell us this particular patient, three short episodes in, is already past the point where watchful waiting is reasonable.
You're both arguing about timing; I want to flag what the drug itself requires before either of you commits her to it. Flecainide is only appropriate here because her echocardiogram already ruled out structural heart disease — start it in a patient with even mild left ventricular impairment or coronary disease and you're walking straight into what CAST actually demonstrated — excess mortality when a class Ic agent is given to patients with structural heart disease after myocardial infarction, which is where the contraindication comes from in the first place. And it can't be given alone: at maintenance doses, flecainide can organize fibrillation into atrial flutter with 1:1 AV conduction, driving the ventricular rate up rather than down, which is why it's never prescribed without a concurrent AV-nodal blocker on board.
If she starts it, it's flecainide plus a low-dose beta-blocker, not flecainide alone — and given the objection about whether she needed a drug at all, I'd build in an explicit re-look, not just start and hope: echo and rhythm reassessment at six months, so "starting early" doesn't quietly become "started forever" without ever checking whether it was the right call.
Agreed, after Clinical Pharmacology's addition: flecainide 50 mg twice daily plus metoprolol succinate 25 mg daily, started together rather than sequentially, given the 1:1-conduction risk. Apixaban continues unchanged.
The disagreement about whether she needed a drug at all doesn't resolve by starting one; it resolves by checking. Echocardiogram and rhythm reassessment are scheduled at six months, not as routine follow-up but as the actual test of Primary Care's objection — if she's stayed in sinus rhythm and tolerated the drug well, early rhythm control looks like it did what the trial evidence predicted. If she hasn't, the group agreed the honest reading is that this was never an arrhythmia flecainide was going to fix, and rate control was the right call from six weeks in.
W.O., a 74-year-old man who spent decades as a machinist before retiring, now spends most mornings on his dock trying to convince crappie to bite. He has been in atrial fibrillation continuously since it was first found on a routine physical two years ago — an incidental finding at the time, since he'd had no palpitations at all, only the vague sense that he was more short of breath climbing into his boat than he used to be. He has carried hypertension for over fifteen years, treated but not always tightly controlled, and it's that same hypertensive strain on his heart that both contributed to his atrial fibrillation and has kept building on top of it ever since.
An echocardiogram obtained this visit, prompted by his wife's observation that he'd stopped taking the boat out most weeks, shows a left atrium measuring 5.6 cm — severely dilated, more than a centimeter beyond normal — with mild diastolic dysfunction and an ejection fraction that is otherwise preserved. Two years of continuous fibrillation is enough time for the atrium to have not just stretched but structurally reorganized around the arrhythmia: fibrotic replacement of atrial tissue that doesn't reverse simply because the rhythm is restored, which is precisely why a chamber this size predicts a low probability that any cardioversion, drug-assisted or electrical, would hold. His current metoprolol succinate 50 mg isn't controlling his rate adequately either — his resting heart rate today was 105 — so simply continuing what he's on isn't really an option regardless of which broader strategy gets chosen.
I'd accept rate control here and stop chasing rhythm. AFFIRM already answered this in aggregate — in patients where maintaining sinus rhythm is unlikely, a rate-control strategy performs at least as well as rhythm control on hard outcomes, without the drug and procedural risk of repeatedly trying to convert someone back. A left atrium at 5.6 centimeters after two years of continuous fibrillation isn't a soft number; it's a fairly reliable predictor that any cardioversion we attempt won't hold, whether we get there with a drug or a shock. I don't think we owe him another attempt at a rhythm that's unlikely to survive the drive home.
The odds are genuinely worse than L.N.'s case — I won't argue that — but "unlikely to hold" isn't the same as "not worth attempting," especially with ablation rather than drugs or cardioversion alone. Success rates in longstanding persistent AF are meaningfully lower than in paroxysmal disease, not zero, and he's not asymptomatic — he's stopped taking his boat out. That's a real functional decline, not a lab value, and I don't think an echocardiogram gets to override what he's telling us about his own life without at least offering him the referral and letting him weigh the odds himself.
To be clear, flecainide isn't part of this conversation for him either way — his atrium takes that option off the table regardless of which side of this argument wins. The ablation-versus-rate-control question is a separate one.
Before either of you sends him toward a rhythm-control conversation, I'd want to know his rate is actually adequate first — it currently isn't. A resting heart rate of 105 on metoprolol alone is undertreated rate control, and undertreated rate control produces exactly the fatigue and exercise intolerance being read right now as evidence he needs rhythm control. Switch him to diltiazem, get his rate genuinely controlled, and see him back in six to eight weeks. If he's still limited once his rate is actually where it should be, that's real evidence for the referral. If he's not, we've avoided a procedure with real risk in a 74-year-old for a problem that turned out to be dosing, not rhythm.
Agreed: switch from metoprolol succinate to diltiazem, extended-release, as the new primary rate-control agent, with digoxin held in reserve if his resting rate stays above goal. Flecainide is off the table entirely. Referral for an electrophysiology consultation regarding catheter ablation is placed today, but its outcome depends on what happens over the next six to eight weeks of adequate rate control.
Not agreed, and the reason the referral doesn't commit him to a procedure yet:
His functional decline was a rate problem, not a rhythm problem, and the ablation conversation can wait or close entirely.
The fatigue was never just about rate, and the ablation referral proceeds on its own guarded but real chance of restoring sinus rhythm even in a chamber this remodeled.
Cardiology and electrophysiology left the visit disagreeing about how much weight his symptoms should carry against an echocardiogram this discouraging; nobody set a probability on the ablation succeeding if it comes to that. Geriatrics set the actual next checkpoint instead — a follow-up visit at eight weeks to find out which version of this problem he actually has.